...
首页> 外文期刊>British Journal of Cancer >A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management
【24h】

A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management

机译:超过11年的胸腺上皮肿瘤的单一机构经验:临床特征和结果以及对未来治疗的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Thymic epithelial tumours (TETs), the most common tumour of the anterior mediastinum, are epithelial neoplasms of the thymus with a wide spectrum of morphologic features. We retrospectively analysed clinical features of TET and the correlation of World Health Organisation (WHO) histologic classification and Masaoka staging system with different treatment modalities in 195 patients, from 1995 to 2005. According to the Masaoka's staging system, there were 78 (40.0 %) patients with stage I, 38 (19.5%) with stage II, 41 (21.0%) with stage III, 38 (19.5%) with stage IV. All patients were reclassified according to the WHO criteria as follows: Type A (n=9, 4.6%), AB (n=37, 18.9%), B1 (n=29, 14.8%), B2 (n=48, 24.6%), B3 (n=40, 20.5%), C (n=32, 16.4%). There was a fairly good correlation between Masaoka staging and WHO histotype (PPPn=57) had more favourable disease-free and overall survival as compared with those without adjuvant treatment (n=20) (P=0.015, 0.015, respectively). Given that the predominant sites of recurrence after surgery was pleura/pericardium and lung, and the fact that complete resection was a significant influential factor for survival at log–rank test, an active investigation of newer treatment strategies such as neoadjuvant treatment to improve the resectability and development of optimal adjuvant treatment modality is a high priority especially for those with high-risk for recurrence or in patients with advanced stage disease.
机译:胸腺上皮肿瘤(TETs)是前纵隔最常见的肿瘤,是胸腺的上皮肿瘤,具有广泛的形态学特征。我们回顾性分析了1995年至2005年间195例患者的TET的临床特征以及世界卫生组织(WHO)组织学分类和Masaoka分期系统与不同治疗方式的相关性。根据Masaoka的分期系统,有78例(占40.0 % )I期患者,其中II期患者38(19.5%),III期患者41(21.0%),IV期患者38(19.5%)。所有患者均根据WHO标准重新分类如下:A型(n = 9,4.6 %),AB(n = 37,18.9 %),B1(n = 29,14.8 %),B2(n = 48、24.6%,B3(n = 40、20.5%),C(n = 32、16.4%)。与未经辅助治疗的患者(n = 20)相比,正冈分期与WHO组织型(PPPn = 57)之间的相关性更好,无疾病生存期和总体生存期更佳(n = 20)(分别为P = 0.015、0.015)。鉴于手术后的主要复发部位是胸膜/心包和肺,并且完全切除是对数秩检验生存的重要影响因素,因此积极研究了新的治疗策略,例如新辅助治疗,以提高可切除性尤其对于那些具有高复发风险的患者或患有晚期疾病的患者,最佳辅助治疗方式的开发尤为重要。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号